shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data
Abstract
Individual cancers rely on distinct essential genes for their survival. The Cancer Dependency Map (DepMap) is an ongoing project to uncover these gene dependencies in hundreds of cancer cell lines. To make this drug discovery resource more accessible to the scientific community we built an easy-to-use browser, shinyDepMap (https://labsyspharm.shinyapps.io/depmap). shinyDepMap combines CRISPR and shRNA data to determine, for each gene, the growth reduction caused by knockout/knockdown and the selectivity of this effect across cell lines. The tool also clusters genes with similar dependencies, revealing functional relationships. shinyDepMap can be used to 1) predict the efficacy and selectivity of drugs targeting particular genes; 2) identify maximally sensitive cell lines for testing a drug; 3) target hop, i.e., navigate from an undruggable protein with the desired selectivity profile, such as an activated oncogene, to more druggable targets with a similar profile; and 4) identify novel pathways driving cancer cell growth and survival.
Data availability
Data files have been provided for Figures 1, 3, 4, and 5 on FigShare: https://figshare.com/projects/shinyDepMap_Source_Data/97382 (DOIs: 10.6084/m9.figshare.13653251.v1, 10.6084/m9.figshare.13653257.v1, 10.6084/m9.figshare.13653260.v1, 10.6084/m9.figshare.13653266.v1, 10.6084/m9.figshare.13653272.v1, 10.6084/m9.figshare.13653278.v1, 10.6084/m9.figshare.13653281.v2)
-
shinyDepMap - Source Data 1FigShare, doi:10.6084/m9.figshare.13653251.
-
shinyDepMap - Source Data 2FigShare, doi:10.6084/m9.figshare.13653257.v1.
-
shinyDepMap - Source Data 3FigShare, doi:10.6084/m9.figshare.13653260.v1.
-
shinyDepMap - Source Data 4FigShare, doi:10.6084/m9.figshare.13653266.v1.
-
shinyDepMap - Source Data 5FigShare, doi:10.6084/m9.figshare.13653272.v1.
-
shinyDepMap - Source Data 6FigShare, doi:10.6084/m9.figshare.13653278.v1.
-
shinyDepMap - Source Data 7FigShare, doi:10.6084/m9.figshare.13653281.v2.
Article and author information
Author details
Funding
Japan Society for the Promotion of Science (H29-814)
- Kenichi Shimada
National Institute of General Medical Sciences (R35GM131753)
- Timothy J Mitchison
National Cancer Institute (U54-CA225088)
- Jeremy L Muhlich
Defense Advanced Research Projects Agency (W911NF-15-1-0544)
- John A Bachman
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Erica A Golemis, Fox Chase Cancer Center, United States
Version history
- Received: March 20, 2020
- Accepted: February 6, 2021
- Accepted Manuscript published: February 8, 2021 (version 1)
- Accepted Manuscript updated: February 10, 2021 (version 2)
- Version of Record published: March 2, 2021 (version 3)
Copyright
© 2021, Shimada et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 20,898
- views
-
- 1,231
- downloads
-
- 47
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Genetics and Genomics
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.
-
- Cancer Biology
- Cell Biology
Rapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of proteasome inhibitors is upregulated by the transcription factor Nrf1 (NFE2L1), which is activated by a DDI2 protease. Here, we demonstrate that the recovery of proteasome activity is DDI2-independent and occurs before transcription of proteasomal genes is upregulated but requires protein translation. Thus, mammalian cells possess an additional DDI2 and transcription-independent pathway for the rapid recovery of proteasome activity after proteasome inhibition.